EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

Hermine I Brunner iD, Anna Shmagel iD, Gerd Horneff iD, Ivan Foeldvari, Jordi Antón iD, Athimalaipet V Ramanan iD, Yuli Qian iD, Kristina Unnebrink, Shuai Hao, Heidi S Camp, Nasser Khan, Wei Liu iD und 1 weitere

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25465 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Hermine I Brunner und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati, Cincinnati Children's Hospital Medical Center, Ohio. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Juvenile, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA).

Methods

In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, JuvenileHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsAdolescentChildChild, PreschoolFemaleHumansMaleAdministration, OralTreatment Outcome

Substanzen

Antirheumatic AgentsHeterocyclic Compounds, 3-RingJanus Kinase Inhibitorsupadacitinib

Autor:innen und Institutionen

  • University of Cincinnati, Cincinnati Children's Hospital Medical Center, Ohio.
  • AbbVie Inc., North Chicago, Illinois.
  • Asklepios Clinic Sankt Augustin, Sankt Augustin, and University Hospital of Cologne, Cologne, Germany.
  • Hamburger Zentrum für Kinder und Jugendrheumatologie, am Klinikum Eilbek, Hamburg, Germany.
  • Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
  • Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom.

ORCID-Profile: Hermine I Brunner, Anna Shmagel, Gerd Horneff, Jordi Antón, Athimalaipet V Ramanan, Yuli Qian, Wei Liu, Mohamed-Eslam F Mohamed

Förderung

  • AbbVie

Zitieren

APA

Brunner, H. I., Shmagel, A., Horneff, G., Foeldvari, I., Antón, J., Ramanan, A. V., Qian, Y., Unnebrink, K., Hao, S., Camp, H. S., Khan, N., Liu, W., & Mohamed, M. F. (2025). Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial. Arthritis Care & Research. https://doi.org/10.1002/acr.25465

Vancouver

Brunner HI, Shmagel A, Horneff G, Foeldvari I, Antón J, Ramanan AV, et al. Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial. Arthritis Care & Research. 2025. doi:10.1002/acr.25465

BibTeX
@article{Brunner2025,
  author = {Brunner, Hermine I and Shmagel, Anna and Horneff, Gerd and Foeldvari, Ivan and Antón, Jordi and Ramanan, Athimalaipet V and Qian, Yuli and Unnebrink, Kristina and Hao, Shuai and Camp, Heidi S and Khan, Nasser and Liu, Wei and Mohamed, Mohamed-Eslam F},
  title = {Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25465}
}
Kostenlos starten →